SEARCH:   Advanced

Blood, 16 April 2009, Vol. 113, No. 16, pp. 3809-3812. Prepublished online as a Blood First Edition Paper on February 4, 2009; DOI 10.1182/blood-2008-10-185280. This Article Full Text (PDF) All Versions of this Article: blood-2008-10-185280v1 113/16/3809    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hilchey, S. P. Articles by Bernstein, S. H. Search for Related Content PubMed PubMed Citation Articles by Hilchey, S. P. Articles by Bernstein, S. H. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted October 20, 2008 Accepted January 27, 2009 Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab Shannon P. Hilchey, Ollivier Hyrien, Tim R. Mosmann, Alexandra M. Livingstone, Jonathan W. Friedberg, Faith Young, Richard I. Fisher, Raymond J. Kelleher Jr., Richard B. Bankert, and Steven H. Bernstein* James P. Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States David H. Smith Center for Vaccine Biology and Immunology, Aab Institute of Biomedical Sciences, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States The Witebsky Center for Microbial Pathogenesis and Immunology, State University of New York at Buffalo School of Medicine, Buffalo, NY, United States * Corresponding author; email: steven_bernstein{at}urmc.rochester.edu. The incorporation of rituximab, a chimeric anti-CD20 monoclonal antibody, into the therapeutic armamentarium for patients with follicular lymphoma (FL) has significantly improved treatment outcome for such patients. Despite the almost universal application of this therapy however, its exact mechanism of action has not been completely defined. One proposed mechanism is that of a "vaccinal effect", whereby FL cell kill by rituximab results in the elicitation of a FL specific T-cell response. The demonstration that rituximab can even elicit such a response in patients, has to our knowledge, never been shown. We analyzed the response against the immunoglobulin expressed by the FL before and after rituximab monotherapy in five FL patients and found an increase in FL idiotype specific T-cells post-rituximab in 4/5 patients. Our data thus provide "proof of principle" for the ability of passive immunotherapy with rituximab to elicit an active FL specific cellular response. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. G. Ramsay, A. J. Clear, G. Kelly, R. Fatah, J. Matthews, F. MacDougall, T. A. Lister, A. M. Lee, M. Calaminici, and J. G. Gribben Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy Blood, November 19, 2009; 114(21): 4713 - 4720. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020